Age median (range), (y.o.) | 50 (33–74) |
---|---|
Metastatic de-novo or recurrent, (n) | |
Metastatic de-novo | 10 (27.8%) |
Metastatic recurrent | 26 (72.2%) |
Subtype | |
Luminal | 29 (80.6%) |
Triple negative | 7 (19.4%) |
Number of previous chemotherapy regimens, (n) | |
0 | 22 (61.1%) |
1 | 10 (27.8%) |
2 | 2 (5.6%) |
≧3 | 2 (5.6%) |
Previous endocrine therapy, (n) | 26 (72.2%) |
Metastatic sites, (n) | |
Visceral | 23 (63.9%) |
Non-visceral | 13 (36.1%) |